Table 2 Laboratory examination of 288 patients with mercury poisoning

Blood mercury content ^a,medain(IQR),µg/L

9.35 (4.20 to 21.00)

I Vs II Vs III

10.77

0.005

Non-complication, I

8.20 (3.60 to 20.60)

III Vs II

5.26

0.022

Nephrotic syndrome^d, II

16.70 (7.80 to 37.80)

II Vs I

10.47

0.001

Peripheral nerve injury^d, III

10.20 (5.20 to 17.20)

III Vs I

0.35

0.554

Urine mercury content ^a,medain(IQR),µg/L

13.50 (5.10 to 29.60)

I Vs II Vs III

4.68

0.096

Non-complication, I

13.25 (4.9 to 29.1)

III Vs II

4.18

0.041

Nephrotic syndrome, II

20.9 (8.3 to 37.8)

II Vs I

3.17

0.075

Peripheral nerve injury, III

9.5 (4.9 to 20)

III Vs I

0.93

0.335

Creatinine,medain(IQR),µmol/L

56 (49 to 66)

UMC^a,medain(IQR),µmol/molb

128.57 (40.35 to 277.22)

I Vs II Vs III

3.32

0.19

Non-complication, I

125.18 (37.68 to 269.84)

III Vs II

2.63

0.105

Nephrotic syndrome, II

205.38 (70.34 to 411.36)

II Vs I

2.89

0.089

Peripheral nerve injury, III

221.95 (93.51 to 472.06)

III Vs I

0.11

0.746

24-h urinary protein, median (IQR), g/24 h

0.42 (0.26 to 2.75)

Renal biopsy^b, n(%)^c

39 (13.5 %)

24.10

< 0.001

MN

20 (51.3 %)

MCN

14 (35.9 %)

MSPGN

3 (7.7 %)

FSGS

2 (5.1 %)

EMG^b, n(%)

39 (13.5 %)

6.79

0.036

Neuropathy

33

Myopathy

1

FW

5